gsbr-1290
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 9, 2023 (NCT05762471)
Timeline
Indications
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCP(=O)(CC)c1ccc(-n2ccn(-c3c4c(nn3-c3cc(C)c(F)c(C)c3)CCN(C(=O)c3cc5cc(C6CCOCC6)ccc5n3[C@@]3(c5nc(=O)o[nH]5)C[C@@H]3C)[C@H]4C)c2=O)cc1NC- Mol. weight
- 916.01 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068040 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07169942 | Phase 2 | Aug 15, 2025 | Structure Therapeutics |
| NCT06703021 | Phase 2 | Dec 31, 2024 | Structure Therapeutics |
| NCT06693843 | Phase 2 | Oct 17, 2024 | Structure Therapeutics |
| NCT06139055 | Phase 1 | Oct 2, 2023 | Gasherbrum Bio, Inc |
| NCT05893043 | Phase 1 | Apr 24, 2023 | Gasherbrum Bio, Inc |
| NCT05762471 | Phase 1/Phase 2 (Phase 2) | Jan 9, 2023 | Gasherbrum Bio, Inc |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gasherbrum Bio, Inc | For profit | 3 | 3 | 2 | 2023 |
| Structure Therapeutics | For profit | 3 | 3 | 1 | 2024 |
2 organizations
Page 1 / 1